PD1-Vaxx is now progressing in colorectal cancers (CRC) in a Phase2 study in earlier lines of disease (pre-surgery). The pivot away from NSCLC to CRC has been made to maximise the potential of PD1-Vaxx for earlier data read outs and for registrational pathways for our product.
Sirwes, thank you for sharing Imugene's future direction for HER-vaxx.
IMO, Imugene's shared study costs V future rewards for the CRC PD1-Vaxx Phase 2 study is exceptional, well done Leslie Chong.(The Australian study costs will qualify for a Government rebate).
Regards.
IMU product line - HER-Vaxx, page-30
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $396.8M | |||
| Open | High | Low | Value | Volume |
| 5.4¢ | 5.4¢ | 5.3¢ | $339.4K | 6.365M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 895592 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 672708 | 10 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |